CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement

2013-04-08 - English

This information was released for public disclosure on April 8, 2013 at 8.25 am CET.

CellaVision broadens cooperation with global leading manufacturer of biomedical testing instrument systems Beckman Coulter by adding EMEA to their existing global distribution agreement. The agreement gives Beckman Coulter a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide, except Canada and Japan, from April 8, 2013*.

"We enhance the agreement with Beckman Coulter to also include the EMEA market. Beckman Coulter provides us with a very strong sales channel and the ability to continue increasing our market penetration in this region. Parallel sales channels in most countries around the world is an important piece of our long term strategy", says Yvonne Mårtensson, CEO of CellaVision.

Beckman Coulter and CellaVision have been developing their partnership since 2010, when they partnered in the USA, Latin America and Asia-Pacific, including China and India. Hematology products covered in the agreement, such as the CellaVision® DM96 and DM1200, are used by clinical laboratories for automated medical microscopy analysis. Beckman Coulter can now offer their customers a complete solution to help improve workflow efficiency, a requirement of many mid-size and large size laboratories.

EMEA, especially Europe, is one of CellaVision's major growth markets. The transition from manual microscopy to CellaVision's digital method has been continually increasing over the years in the European countries. In 2012 Europe accounted for 33 percent of the company's total sales, North America for 60 percent and Asia Pacific for 7 percent.

* In 2012 separate agreements were signed for Sweden, Norway and Denmark. These agreements differ from the global distribution agreement in that CellaVision is responsible for installation and support.

For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82 | Email: yvonne.martensson@cellavision.com  

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.  

This information is disclosed by CellaVision AB (publ) pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public disclosure on April 8, 2013 at 8.25 am CET.

PDF version: Press release as PDF

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register

Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


ABG Sundal Collier AB
Sten Gustafsson
+46 8 566 286 93

Pareto Securities AB
Christian Lee
+46 8 402 52 67


Access our Student Resources

To access this resource, please provide the following information about yourself.